A new formulation of ibuprofen is getting scientists excited because it looks like it will provide superior pain relief by allowing people to take higher doses without the cardiovascular side effects found with current formulations.
In a research report published online in The FASEB Journal, scientists used mice to show that ibuprofen arginate is better tolerated and is released into the bloodstream faster, which can provide faster pain relief.
“While more experiments are required, our observations show that ibuprofen arginate provides, in one preparation, a COX-2 inhibitor and arginine supplement,” said Jane A. Mitchell, Ph.D., a researcher involved in the work and Head of Cardiothoracic Pharmacology, Cardiothoracic Pharmacology and Vascular Biology Section at the National Heart and Lung Institute at the Institute of Cardiovascular Medicine and Science at the Imperial College in London, England.
“Whilst remarkably simple, our findings are potentially game-changing in the pain medication arena,” she added.
The scientists used a range of approaches from experiments using single types of cells to whole laboratory animals in which blood pressure was measured.
In the first experiment, mouse cells were studied in dishes where the normal arginine was removed from the growth solution. They found that the arginine contained in ibuprofen arginine could work in exactly the same way that regular arginine works in cells.
The second experiment involved blood vessels from mice and rats, to which an artificial compound to block the protective effects of the normal arginine contained in all tissues, was applied. In this experiment, ibuprofen arginine reversed the block and restored blood vessel function to normal levels.
The third experiment involved measuring blood pressure in live rats and blocking the protective effects of normal arginine in the body, which caused an increase in blood pressure.
Study results demonstrated that ibuprofen arginine worked just like regular arginine to restore blood pressure to normal levels. Arginine formulations of ibuprofen could act to negate the harmful cardiovascular consequences caused by high doses of these common anti-inflammatory painkillers.
“This is a nifty idea and the results are clear”,” said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal. “The potential for human use is attractive, not only for attenuating the cardiovascular risk, but also to the extent that this formulation may circumvent moving certain patients onto opioid painkillers, fraught with their own dangers.”